Login to Your Account

Other News To Note

Wednesday, July 24, 2013

• Imprimis Pharmaceuticals Inc., of San Diego, acquired intellectual property for IPI-120, a formulation of tranexamic acid and a derivative of lysine, and an antibiotic. The acquisition was part of an asset purchase agreement with Buderer Drug Company. The combination of tranexamic acid and antibiotic is designed to provide clotting plus protection against infection in transdermal, local, intra-wound applications or intracavity instillation formulations. Terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription